Craft
KRKA

KRKA

Revenue

€1.6 B

FY, 2021

KRKA Summary

Company summary

Overview
KRKA is a generic pharmaceutical company, which engages in the development, production, marketing, and sale of prescription pharmaceuticals, non-prescription products, and animal health products. The Company's prescription pharmaceuticals include medicines for the treatment of cardiovascular diseases, central nervous system diseases, diseases of the alimentary tract and metabolism, infections, diseases of the blood and blood-forming organs, diseases of the urinary tract, diseases of the respiratory system, and oncology.
Type
Public
Status
Active
Founded
1954
HQ
SI | view all locations
Website
https://www.krka.biz
Cybersecurity rating
ESG rating
60-79 out of 100|View all ESG data
Sectors

LocationsView all

1 location detected

  • Novo mesto HQ

    Slovenia

    6 Šmarješka cesta

KRKA Financials

Summary financials

Revenue (Q3, 2022)
€384.8M
Gross profit (Q3, 2022)
€276.0M
Net income (Q3, 2022)
€65.5M
Cash (Q3, 2022)
€292.3M
EBIT (Q3, 2022)
€94.5M

Footer menu